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Verticillins are a class of dimeric epipolythiodioxopiperazine alkaloids that are 
known to have IC50 values of 10 nM or less in various human cancer cell lines This 
biological activity makes them potential candidates in the search of new anticancer drugs. 
However, further studies are hindered by limited supply when isolating verticillin class 
secondary metabolites from fungal sources. Thus, the search for fungal strains that 
produce these secondary metabolites at equal or greater abundances than the fungal strain 
currently being used in our lab, MSX59553, is necessary. This study revealed MSX59549 
as a fungal strain of interest due to its production of verticillin A and verticillin H in 
higher abundances than MSX59553. Three additional fungal strains, MSX39480, 
MSX43578 and MSX60138, were also found to produce more verticillin H than 
MSX59553. These results lead to optimizing the isolation of verticillins for use in future 
chemical and pharmacological studies. 
The generation of fluorinated verticillin derivatives has been achieved using 
precursor directed biosynthesis to incorporate 5-fluorotryptophan into the verticillin 
structures while retaining the potent biological activity. Further precursor directed 
biosynthesis experiments using 5-hydroxytryptophan, 5-chlorotryptophan and 5-
bromotryptophan lead to the production of 9-hydroxyverticillin A and 9-chloroverticllin 
A. Further studies involving the isolation of these verticillin derivatives and 
 
semisynthetic modification via cross coupling reactions may improve pharmacological 
properties within the verticillin class. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Verticillin Class Compounds 
Fungi are an abundant source of structurally diverse and biologically active 
secondary metabolites.1-3 Fungal secondary metabolites have been utilized as 
antibacterial and antifungal drugs, such as, penicillin and griseofulvin, respectively. In 
continuing the search for anticancer secondary metabolites from filamentous fungi,4, 5 
epipolythiodioxopiperazine (ETP) alkaloids have become a promising group due to their 
unique structure and activity. Verticillins, as an important member of ETP alkaloids, are a 
lead class of dimeric structures that exemplify potent antitumor activity,6-10 along with 
antibacterial,11-14 nematicidal15 and immune induction properties.16  
Verticillin A was first isolated in 1970 from what was first reported to be a 
Veriticillium sp., at which point they were only able to characterize the disulfide-bridged 
diketopiperazine system using 1H NMR, IR and mass spectrometry.17 It was not until one 
year later that the complete structure and absolute configuration was elucidated using 
chemical and physicochemical experiments.12 In 2011 it was determined that the 
Veriticillium sp. was unlikely to produce verticillin A due to the absence of ETP gene 
clusters. It was suggested that the fungal culture was contaminated with Clonostachys 
2 
rosea, formerly known as Gliocladium roseum, which could have been responsible for 
the biosynthesis of verticillin A.18 
Analogues of verticillin A were first discovered in 1973 and the first total 
synthesis of  (+)-11, 11’-dideoxyverticillin A was considered to be a big step forward due 
to the complexity of the verticillin structural core.19, 20 Verticillin H, the most recent 
analogue, was isolated from a Clonostachys sp. (Bionectriaceae) and tested for 
cytotoxicity in various cancer cell lines. These tests showed potent activity in human 
breast carcinoma, large cell lung carcinoma and astrocytoma at the same order of 
magnitude as the positive control drug, camptothecin.4 Verticillins are an interesting class 
of ETP alkaloids that are characterized by their dimeric core and the disulfide bridge that 
is responsible for their potency.21 The combination of all of these characteristics make 
verticillins desirable for further pharmacological use. 
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Figure 1. Structures of Verticillin A and Related Analogues. 
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1.2 Verticillin Supply 
A common problem pursuing these compounds of interest is their low abundance, 
which in turn limits supply for pharmacological studies. In past studies, various fungal 
strains and growth conditions have been compared to optimize verticillin isolation. The 
results indicated that Clonostachys rogersoniana (MSX59553) produced more verticillin 
related compounds when grown on oatmeal media.22 Twelve fungal strains, provided by 
Mycosynthetix, Inc., were analysed in this study to further optimize the isolation of 
verticillins and verticillin analogues. 
1.3 Verticillin Modification 
Approximately 20% of all pharmaceutical drugs on the market today contain 
fluorine because of its ability to improve pharmacological properties.23-28 Verticillins are 
derived from multiple amino acids and believed to be biosynthesized via non-ribosomal 
peptide synthases (NRPSs).29 Previous studies to incorporate fluorine into verticillin 
structures have applied this hypothesis by providing 5-fluoro-DL-tryptophan (5-F-DL-
tryptophan) to fungal cultures. This experiment resulted in the isolation and 
characterization of 9-fluoroverticillin A, 9,9’-difluoroverticillin A, 9-fluoroverticillin H 
and 9,9’-difluoroverticillin H (Figure 2).30 When these modified verticillins were tested 
against human breast, ovarian cancer and melanoma cell lines; the cytotoxicity results 
showed retention of biological activity (Table 1). 
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Figure 2. The Structures of Verticillin A, Verticillin H and the Fluorinated Analogues. 
 
This biosynthetic approach for modification helps maintain the integrity of the 
core structure and thus activity. With a variety of modified tryptophan commercially 
available, we can pursue additional precursor directed biosynthesis experiments for the 
diversification of verticillin compounds. 
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Table 1. Cytotoxicities of Verticillin A, Verticillin H and Fluorinated Analogues. 
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1.4 Cross-Coupling Reactions 
Natural product biological activity can be improved upon via semisynthetic 
reactions. The targeted verticillin modifications will enhance reactivity for semisynthetic 
reactions, specifically cross-coupling reactions. The Suzuki-Miyaura reaction has been 
used for various synthetic experiments due to its flexibility and mild conditions.31, 32 The 
use of this reaction in natural product research has led to the engineering of natural 
product derivatives with improved biological activities.33, 34 Targeting the addition of 
halides and hydroxy groups to the tryptophan moiety of  the verticillin structure 
establishes potential reactive centers for Suzuki-Miyaura and phenol cross-coupling 
reactions, respectively (Figure 3).35, 36 Modifications of natural products can not only 
enhance biological activity, but also allow for patenting, which is considered to be 
significant when trying to commercialize a drug.37 The modification of verticillin class 
compounds via precursor directed biosynthesis followed by semisynthetic reactions can 
lead to improved biological activity as well as open the door for patentability. 
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Figure 3. Cross-Coupling Reactions. The verticillin A structure was simplified to focus 
on the tryptophan moiety. The proposed Suzuki-Miyaura reaction for the chlorinated and 
brominated verticillin analogues (A). The proposed cross-coupling reactions for the 
hydroxylated verticillin analogues (B).31, 36 
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CHAPTER II 
OPTIMIZING ISOLATION OF VERTICILLIN SECONDARY METABOLITES 
 
2.1 Experimental 
2.1.1 Fungal Fermentation 
Each fungal strain is maintained on oatmeal agar in Petri dishes and transferred 
once a month to a new plate. In order to scale up culturing, a fungus is grown on solid 
media. A mycelium agar plug from the Petri dish is transferred to Yeast Extract Soy 
Peptone Dextrose (YESD) broth to yield a seed culture. The seed culture is then 
incubated for three days at room temperature with agitation (~100 rpm). A 250 mL 
Erlenmeyer flask containing 10 g of oatmeal (Quaker) and 17 mL of deionized water is 
autoclaved. A seed culture is transferred to the sterilized flask and left to grow at room 
temperature for 7 to 10 days.  
2.1.2 Extraction and Isolation 
The fungal culture growth on solid media (oatmeal) is ceased using acetone, 
which is then chopped and shaken (~100 rpm) overnight at room temperature. The 
culture is then vacuum filtered, and the remaining residue is washed with acetone. The 
filtrate is then evaporated under vacuum until only water and a precipitate remained. To 
this, a mixture of 2:1 ethyl acetate:water is added, stirred and transferred to a separatory 
funnel. The mixture was left to separate overnight, then the ethyl acetate layer containing 
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the verticillin compounds was collected. The desugared extract is then evaporated to 
dryness under vacuum and defatted with 1:1:2 methanol:acetonitrile:hexane. The 
defatted, 1:1 methanol:acetonitrile layer is collected and evaporated to dryness under 
vacuum. The extract is then subjected to chromatographic separation via normal phase 
flash chromatography and normal phase high performance liquid chromatography 
(HPLC) in order to isolate the secondary metabolites of interest. The flash 
chromatographic separation was performed on a Teledyne ISCO Combiflash Rf system 
connected to an evaporative light scattering detector (ELSD) and a photodiode array 
detector (PDA) with UV detection set at 200-400 nm with a specific wavelength set at 
300 nm. The HPLC separation was completed using a Varian ProStar HPLC system 
connect to a ProStar 355 PDA with UV detection set at 240 and 300 nm. The preparative 
normal-phase HPLC purification was achieved using a silica (5 μm; 250 x 21.2 mm) 
column with a mobile phase consisting of ethyl acetate and hexanes. 
2.1.3 Identification of Verticillin Class Secondary Metabolites 
The isolated metabolites are characterized and identified using a series of 
spectrometric and spectroscopic techniques. The HRMS data is collected on either a 
Thermo LTQ Orbitrap XL mass spectrometer or a Thermo Q Exactive Plus (Thermo 
Fisher Scientific); both equipped with an electrospray ionization source and a Waters 
Acquity UPLC (Waters Corp.) using a BEH C18 column (1.7 μm; 50 mm × 2.1 mm) set 
to a temperature and flow rate of 40ºC and 0.3 mL/min, respectively. The mobile phase 
consists of acetonitrile and water (both acidified with 0.1% formic acid), starting at 15% 
acetonitrile and increasing linearly to 100% over 8 minutes, with a 1.5-minute hold 
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before returning to the starting conditions. The scan range was narrowed (m/z 600 to m/z 
800) in order to optimize detection of secondary metabolites in the verticillin class. The 
NMR data is collected using a JEOL ECS-400 spectrometer equipped with a JEOL 
normal geometry broadband Royal probe and 24-slot autosampler, operating at 400 MHz 
for 1H and 100 MHz for 13C as well as a JEOL ECA-500 spectrometer, operating at 500 
MHz for 1H and 125 MHZ for 13C (Both from JEOL USA, Inc.). MS data and NMR data 
are analyzed using Xcalibur software and MestReNova software, respectively. All data is 
compared to values within the in-house dereplication database, ensuring that the isolates 
are verticillin class compounds. In the case that a secondary metabolite does not match a 
known compound, the structure is elucidated using the spectrometric and spectroscopic 
data gathered. 
2.1.4 Preparation of Fungal Extracts 
The fungal extracts were prepared at a 50 μg/mL concentration in 1.5 mL 
Eppendorf  and 200 μL of the solutions were transferred to an Ansi 96 well – 1 mL plate. 
2.1.5 Preparation of Verticillin A and Verticillin H Standards 
Aliquots of each metabolite were weighed and prepared with 1,1,1,3,3,3-
hexafluoropropanol at a concentration of 1.05 mg/mL, then 0.50 mL of each solution 
were combined in a 1.5 mL Eppendorf tube to yield a solution containing 0.525 mg/mL 
of each metabolite. Using this solution, serial dilutions were conducted to produce 
concentrations ranging from 1 ng/mL to 262144 ng/mL. 
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2.1.6 LC-MS Analysis 
To quantify verticillin A and verticillin H within the fungal extracts, an LC-MS 
analysis was conducted in positive ion mode. The mass spectrometer scanned across a 
mass range of m/z 600 to 800 and a spray voltage of 4 kV. This was coupled with an 
Acquity UPLC system (Waters Corp.), which had a flow rate of 0.3 mL/min and utilized 
a BEH C18 column (2.1 mm x 50 mm, 1.7 μm) that was operated at 40°C. The mobile 
phase consisted of Fisher Optima LC-MS grade acetonitrile:water (both with 0.1% formic 
acid). The gradient began at 15% acetonitrile and linearly increased to 100% acetonitrile 
over 8 min. It was then held at 100% for 1.5 min before returning to starting conditions to 
re-equilibrate. All data was analyzed using Thermo Xcalibur Qual Browser and Thermo 
Xcalibur Quan Browser.  
2.2 Results 
The standard solutions containing verticillin A and verticillin H were ran in 
triplicate to create calibration curves for the concentration of each metabolite. The 
quantitation range for verticillin A and  verticillin H were 16 ng/mL to 2048 ng/mL and 
32 ng/mL to 4096 ng/mL, respectively. These results enable quantification of secondary 
metabolite presence in mixtures such as fungal extracts (Figure 4). 
Mycosynthetix, Inc. provided twelve fungal strains suspected of biosynthesizing 
verticillin compounds which were grown in this experiment to compare the amount of 
verticillin A and verticillin H produced. The fungal strains that produced the most 
verticillin A were MSX59549 and MSX59553 with MSX59549 producing 1.85 % 
verticillin A by mass of extract and MSX59553 producing 1.71 %. The most abundant 
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amounts of verticillin H were produced by MSX39480, MSX43578, MSX59549 and 
MSX60138 at 1.11 % ,1.19 % , 1.23 % and 1.04 % per milligram of extract, respectively. 
Of the twelve fungal strains analysed, four fungal strains (MSX60030, MSX64561, 
MSX70918 and MSX71844) did not biosynthesize detectable amounts of verticillin A 
and verticillin H. MSX64546 was found to produce quantifiable amounts of verticillin A, 
however the amount of verticillin H fell below the quantitation range limit (Figure 5). 
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Figure 4. Standard Curves for Verticillin A (A) and Verticillin H (B). 
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Figure 5. The Percentage of Secondary Metabolites of Interest per Milligram of 
Extract for Each Fungal Strain Grown on Oatmeal. 
 
2.3 Conclusion 
Based on the results from comparing various fungal strains, MSX59549 and 
MSX59553 were used to pursue the isolation of verticillin A and verticillin H. Prior to 
beginning this there was about 20 mg of verticillin A and 10 mg of verticillin H in 
storage. With the use of both MSX59553 and MSX59549, an additional 140 mg of 
verticillin A and 50 mg of verticillin H was isolated thereby decreasing the limitation of 
supply for future studies with these compounds. Continuing efforts to isolate more 
material will advance pharmacological research on verticillin compounds in hopes of 
improving anticancer activity.
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CHAPTER III 
PRECURSOR DIRECTED BIOSYNTHESIS OF VERTICILLINS 
 
3.1 Experimental 
3.1.1 Fungal Culture for Precursor Directed Biosynthesis of Verticillin Derivatives 
Two types of fungal cultures were prepared for this experiment: Petri dish and 
solid media. A 1.125 g sample of 5-hydroxy-DL-tryptophan (5-OH-DL-Trp) powder, 
purchased from Chem-Impex Int’l. Inc., was added to 150 mL of sterilized 50 °C water to 
make a 7500 ppm amino acid stock solution of the modified amino acid. The solution is 
then stirred for 20 minutes to homogenize it, then filtered using a sterile Nalgene™, 
0.45μm filter. For the Petri dish fungal culture, an amino acid oatmeal agar solution was 
prepared by combining 20 mL of the latter solution and 200 mL of oatmeal agar solution. 
An agar plug was then transferred to the amino acid oatmeal agar plate and left to grow at 
room temperature for 7 - 10 days. This procedure was also used to make Petri dishes 
containing 5-chloro-DL-tryptophan (5-Cl-DL-Trp)  and 5-bromo-DL-tryptophan (5-Br-
DL-Trp) (Figure 6). 
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Figure 6. Chemical Structures of the Modified Tryptophans. 
 
To prepare the solid media fungal culture, a seed culture was started by 
combining 1 mL of 7500 ppm amino acid stock solution and 10 mL of YESD broth in a 
falcon tube. This was then inoculated with an agar plug taken from a fungal culture 
grown on oatmeal agar. The seed culture was shaken (~100 rpm) at room temperature for 
5 days. A 250 mL Erlenmeyer flask containing 10 g of oatmeal (Quaker) and 15 mL of 
deionized water is autoclaved. The seed culture along with 2 mL of 7500 ppm amino acid 
stock solution was transferred to the sterilized flask, then left to grow at room 
temperature for 7 to 10 days.  
3.1.2 Extraction of Fungal Cultures 
In this study, two extraction methods are used: Petri dish (oatmeal agar) and solid 
media (oatmeal). For the former, the culture is chopped using a spatula and transferred to 
a scintillation vial. The vial is then filled with acetone and left to sit for 4 hours before 
being vortexed and filtered. The extract is then dried under nitrogen before being 
subjected to further analysis. For the latter, the fungal culture growth is ceased using 
acetone, and then it is chopped and shaken (~100 rpm) overnight at room temperature. 
The culture is then vacuum filtered, and the remaining residue is washed with acetone. 
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The filtrate is then evaporated under vacuum until only water and a precipitate remained. 
To this, a mixture of 2:1 ethyl acetate:water is added, stirred and transferred to a 
separatory funnel. The ethyl acetate layer contains the verticillins, while the water 
removes unnecessary sugars. The desugared extract is then evaporated to dryness under 
vacuum and defatted with 1:1:2 methanol:acetonitrile:hexane. The defatted, 1:1 
methanol:acetonitrile layer is collected and evaporated to dryness under vacuum. 
3.1.3 Identification of Modified Verticillin Derivatives 
The HRMS data is collected on either a Thermo LTQ Orbitrap XL mass 
spectrometer equipped with an electrospray ionization source and a Waters Acquity 
UPLC (Waters Corp.) using a BEH C18 column (1.7 μm; 50 mm × 2.1 mm) set to a 
temperature and flow rate of 40ºC and 0.3 mL/min, respectively. The mobile phase 
consists of acetonitrile and water (both with 0.1% formic acid), starting at 15% 
acetonitrile and increasing linearly to 100% over 8 minutes, with a 1.5-minute hold 
before returning to the starting conditions. The scan range was narrowed (m/z 600 to m/z 
800) in order to optimize detection of secondary metabolites of interest. Similar to the 
results obtained during the incorporation of fluorine into verticillin structures, it is 
expected that the modification can appear at the 9 and 9’ positions of the verticillin core 
structure. For verticillin A and verticillin H, it is expected that each compound will have 
two analogues per modified tryptophan (Figure 7). 
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Figure 7. Expected Secondary Metabolites from Precursor Directed Biosynthesis. 
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3.2 Results 
A series of verticillin secondary metabolites naturally metabolised by 
Clonostachys spp. were extracted and isolated for analysis via UPLC-MS. The 
identification and purity of each standard was supported using NMR and MS analysis 
(Figure 8 and 9).  
 
 
 
Figure 8. (+)-ESI Base Peak Chromatogram and Total Scan PDA of Verticillin B.  
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Figure 9. (+)-ESI Mass Spectrum of Verticillin B. 
 
Each standard was then subjected to tandem mass spectrometry (MS/MS) 
experiments to generate fragmentation patterns for each metabolite (Figure 10). The 
observed retention times and ten most abundant MS/MS fragments were recorded and 
referenced for identification of secondary metabolites (Table 2). 
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Figure 10. (+)-ESI Tandem Mass Spectrum (MS/MS) of Verticillin B. 
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Table 2. Observed (+)-ESI Mass Spectral Data of Naturally Occurring Verticillin 
Compounds. 
 
Compound 
Retention Time 
(min) 
Calculated 
[M+H]+ 
MS/MS Fragments* 
 
Verticillin A 
5.42 697.1031 
633.01 632.28 
615.16 551.25 
465.23 401.22 
383.18 284.13 
233.09 232.11 
 
Verticillin B 
5.30 713.0980 
631.34 649.22 
481.33 465.29 
399.40 383.44 
233.29 266.31 
284.39 567.51 
 
Verticillin H 
6.02 725.1345 
643.09 661.02 
397.26 415.10 
479.22 579.36 
233.05 232.12 
298.20 478.50 
 
Gliocladicillin C 
5.54 741.1293 
659.16 677.04 
413.26 280.16 
495.12 676.40 
397.31 296.16 
479.00 233.06 
*Ten most abundant MS/MS fragments. 
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A control flask of MSX59553 was grown on oatmeal and extracted for UPLC-MS 
analysis. A search for the exact masses of each expected modified verticillin was 
performed to determine if MSX59553 was producing metabolites with similar masses. As 
seen in Figure 11, the extracted ion chromatograms (XICs) produced several peaks that 
can be considered to be within the baseline because they had normalisation levels 4 
orders of magnitude lower than that of the extract. An XIC for the mass of 741.1293 amu 
produced a peak at the retention time that is associated with the presence of gliocladicillin 
C, indicating that MSX59553 naturally metabolites  this verticillin compound. 
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Figure 11. The (+)-ESI-HRMS Analysis of MSX59553 Control. The base peak 
chromatogram of MSX59553 grown on Oatmeal (A). The extracted-ion chromatogram 
(XIC) of  9-hydroxyverticillin A (B), gliocladicillin C/9-hydroxyverticillin (C), and 9-
chloroverticillin A (D).  
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The extract of MSX59553 grown on solid media with 5-OH-DL-Trp was 
analysed via UPLC-HMRS in pursuit of modified verticillin A and verticillin H. The 
expected analogues were 9-hydroxyverticllin A, 9,9’-dihyrdroxyverticillin A, 9-
hydroxyverticillin H, and 9,9’-dihydroxyverticillin H (Figure 7). The production of 
secondary metabolites was first assessed using extracted-ion chromatograms (XICs) by 
searching for their respective mass-to-charge ratios with an accurate mass tolerance of 5 
ppm. In addition to HRMS data, retention times and UV data were also used as mutually 
supportive data. Further analysis in search of  m/z 713.0980, the calculated [M+H]+ of 9-
hydroxyverticillin H and verticillin B,  produced a peak at 4.97 min (Figure 12).  
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Figure 12. The (+)-ESI-HRMS Analysis of MSX59553 Grown with 5-OH-DL-Trp. 
The base peak chromatogram of MSX59553 grown with 5-OH-DL-Trp (A). The 
extracted-ion chromatogram (XIC) of verticillin A (B), 9-hydroxyverticillin A (C), 
verticillin H (D) and gliocladicillin C/9-hydroxyverticillin H (E).  
 
 
When pure verticillin B was analyzed using the same solvents, mass spectrometer, 
and method; it was observed at a retention time of 5.30 min which led to the conclusion 
that the peak at 4.97 min was 9-hydroxyverticillin A. The isotopic pattern of the ion 
found within the peak at 4.97 min was compared to that of a simulated isotopic pattern 
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for 9-hydroxyverticillin A. The comparison yielded very similar results, indicating that 9-
hydroxyverticllin A was responsible for the peak observed at 4.97 min (Figure 13).  
 
 
 
Figure 13. Observed and Expected Isotopic Pattern of 9-Hydroxyverticillin A via 
(+)-ESI HMRS. 
 
 
Ratios of the naturally occurring secondary metabolites to the modified 
metabolites were estimated using the normalisation levels obtained in HRMS analysis. 
The ratios were estimated to be about 1:40 for Verticillin A to 9-hydroxyverticillin A 
(Figure 6). When searching for the presence of 9-hydroxyverticillin H, a peak at 5.55 min 
was observed. However, this peak cannot be identified at the modified compound 
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because the mass and retention time match that of gliocladicillin C. Therefore, it is 
unclear whether 9-hydroxyverticillin H was produced. Similar UPLC-HRMS analyses of 
the Petri dish extracts of MSX59553 with 5-Cl-DL-Trp indicated that the fungus is able 
to produce 9-chloroverticillin A at an estimated ratio of about 1:240 (verticillin to 9-
chloroverticillin A). However, 9-chloroverticillin H was not observed. Extracts of the 
fungus grown with 5-Br-DL-Trp did not indicate the presence of any modified verticillin 
compounds and the peak at 1.52 min was identified as single scan event from an ion that 
appeared near the base of the chromatogram (Figure 14).  
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Figure 14. The (+)-ESI-HRMS Analysis of MSX59553 Grown with 5-Cl-DL-Trp. 
The base peak chromatogram of MSX59553 grown with 5-Cl-DL-Trp (A) and the 
extracted-ion chromatogram (XIC) of 9-chloroverticillin A (B). The (+)-ESI-base peak 
chromatogram of MSX59553 grown with 5-Br-DL-Trp (C) and the extracted-ion 
chromatogram (XIC) of 9-bromoverticillin A (D).  
 
 
Considering that NRPS biosynthesis may be responsible for the incorporation of 
the tryptophan moiety within verticillin structures,29, 30, 38 the success of precursor 
directed biosynthesis in MSX59553 might be limited by the size of the atom or molecule 
being added. The successful incorporation of 5-F-DL-Trp, done previously by Amrine, 
C.S. et al, and 5-OH-DL-Trp to produce isolable amounts of modified verticillins 
31 
compounds has likely been due to their smaller atomic sizes in comparison 5-Cl-DL-Trp 
and 5-Br-DL-Trp30. 
Tandem mass spectrometry (MS/MS) can be utilized to further confirm the 
production of the modified verticillin analogues due to the potential of unique 
fragmentations. ACD/Labs software was used to predict the expected MS/MS 
fragmentation of 9-chloroverticillin A, verticillin B, 9-hydroxyverticillin A, 
gliocladicillin C and 9-hydroxyverticillin H. Most of the MS/MS fragments of 9-
chloroverticillin A would be unique in comparison to the naturally biosynthesized 
secondary metabolites (Table 3). The retention times of verticillin B and 9-
hydroxyverticillin A were observed to be different and to further confirm the identity of 
each peak, the unique MS/MS fragments of each molecule can be used to indicate their 
presence (Table 4). The MS/MS fragments of gliocladicillin C and 9-hydroxyverticllin H 
can be analysed to distinguish between their identical accurate masses (Table 5). 
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Table 3. The Predicted Mass Spectral Data for 9-Cl-Verticillin A via (+)-ESI 
HMRS. 
 
Compound 
Calculated 
[M+H]+ 
Predicted MS/MS Fragments 
 
9-Cl-Verticillin A 
731.0642 
730.0563 712.0458 703.0454 
702.0614 701.0298 699.0141 
696.0686 694.0797 694.0352 
684.0509 676.0691 676.0458 
673.0349 666.1122 664.0966 
655.0243 654.0250 648.1016 
645.0036 642.0581 636.0145 
620.0640 610.0860 602.0534 
528.0693 526.0536 498.0587 
496.0431 480.0481 383.0165 
381.0009 365.0059 362.9903 
349.0555 347.0398 331.0449 
329.0293 234.0133 231.9976 
204.0027 201.9871  
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Table 4. The Predicted Mass Spectral Data for Verticillin B  and 9-OH-Verticillin A 
via (+)-ESI HMRS. 
 
Compound 
Calculated 
[M+H]+ 
Predicted MS/MS Fragments 
 
Verticillin B 
713.0980 
712.0902 695.0637 694.0797 685.0793 
684.0953 683.0637 682.0797 681.048 
678.1025 676.0691 666.0847 664.0691 
658.0797 655.0688 648.1461 648.0919 
646.1304 642.0847 637.0582 636.0589 
630.1335 627.0375 624.0919 619.0324 
618.0484 592.1199 576.125 510.1032 
508.0875 492.0926 480.0926 478.0769 
464.0977 462.082 446.0871 365.0504 
363.0347 349.0555 347.0398 345.0242 
332.0289 331.0449 329.0293 250.0082 
247.9925 234.0133 231.9976 229.982 
219.9976 204.0027 201.9871  
 
9-OH-Verticillin A 
713.0980 
712.0902 694.0797 685.0793 684.0953 
683.0637 681.048 678.1025 676.0691 
666.0847 658.0797 655.0688 648.1461 
646.1304 637.0582 636.0589 630.1335 
627.0375 624.0919 620.064 618.0484 
602.0534 592.1199 510.1032 508.0875 
480.0926 478.0769 462.082 365.0504 
363.0347 349.0555 347.0398 345.0242 
331.0449 329.0293 234.0133 231.9976 
204.0027 201.9871   
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Table 5. The Predicted Mass Spectral Data for Gliocladicillin C and 9-OH-
Verticillin H via (+)-ESI HMRS. 
 
Compound 
Calculated 
[M+H]+ 
Predicted MS/MS Fragments 
 
Gliocladicillin C 
741.1293 
740.1215 722.1110 713.1106 712.1266 
712.0902 711.0950 709.0793 706.1338 
704.1004 696.0953 694.1160 694.0797 
683.1001 678.1025 678.0847 676.1774 
674.1617 672.0953 665.0895 664.0902 
662.1076 658.1668 656.1004 646.0797 
640.1232 606.1355 590.1406 579.1246 
522.1032 506.1082 494.1082 478.1133 
476.0977 460.1028 379.0660 377.0504 
363.0711 361.0555 359.0398 345.0606 
343.0449 264.0238 262.0082 248.0289 
246.0133 243.9976 234.0133 218.0184 
 
9-OH-Verticillin H 
741.1293 
740.1215 722.1110 713.1106 712.1266 
712.0902 711.0950 709.0793 706.1338 
704.1004 698.1110 694.1338 694.1160 
694.0797 683.1001 678.1025 676.1774 
674.1617 672.0953 665.0895 664.0902 
662.1076 658.1668 648.0953 646.0797 
640.1232 630.0847 606.1355 579.1246 
522.1032 494.1082 476.0977 379.0660 
377.0504 363.0711 361.0555 359.0398 
345.0606 343.0449 248.0289 246.0133 
218.0184    
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3.3 Conclusion 
Precursor directed biosynthesis of modified verticillin compounds by the addition 
of 5-OH-DL-Trp to solid media has shown to increase the chemical diversity found 
within MSX59553. Scale up of these growths would yield isolable amounts of 9-
hydroxyverticillin A and help determine if the modified tryptophan was also used to 
biosynthesize 9-hydroxyverticllin H. In addition to the patentable nature of these ‘non-
natural’ natural products, the modifications allow for the possibility for semi-synthetic 
experiments, specifically at the modified position of the tryptophan moiety.
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